“Unleash Your Inner Business Boss: Rosen Receives Investor Praise and Encourages Innovation in Professional Services Industry”

Are You Entitled to Compensation for Your IIPR Securities? Don’t Miss the March 18, 2025 Deadline! Hey there, fellow investor! If you’ve purchased securities of Innovative Industrial Properties, Inc. (NYSE:IIPR) between February 27, 2024 and December 19, 2024, listen up! The Rosen Law Firm wants to remind you of the important March 18, 2025 lead…

Read More

Supreme Court Gets Confused in Immigration Case: What’s Up with Notice Requirements?

Debating Deportation: A Supreme Court Showdown What’s the Fuss About? There seemed to be disagreement within the Supreme Court on Monday over the sufficiency of the notice given by the government to individuals earmarked for deportation hearings. The nearly two-hour debate revolved around whether undocumented immigrants have the right to contest deportation orders if their…

Read More

Levi and Korsinsky: A Reminder for FTAI Aviation Ltd. Investors Regarding Pending Securities Class Action

Understanding Your Options for Recovering Losses from FTAI Aviation Ltd. (FTAI) Investing in the stock market can be an exciting and potentially profitable venture. However, it also comes with risks, and sometimes investments don’t turn out as expected. If you have suffered losses on your investment in FTAI Aviation Ltd. (FTAI) and are seeking to…

Read More

Unraveling Eagle Point Credit Co. LLC’s Q4 2024 Earnings Call: Insights and Highlights from Management

Eagle Point Credit Co LLC (ECC) Q4 2024 Earnings Conference Call: Insights and Analysis On February 20, 2025, at 10:00 AM ET, Eagle Point Credit Company Inc. (ECC) held its fourth quarter 2024 earnings conference call. The call was hosted by Garrett Edson from ICR, Investor Relations, and featured participation from Thomas Majewski, the Chief…

Read More

“Breaking Boundaries: Palisade Bio Chosen for Poster Showcase at Prestigious 2025 Crohn’s & Colitis Conference”

Exciting News from Palisade Bio, Inc. Carlsbad, CA, Jan. 29, 2025 (GLOBE NEWSWIRE) — Palisade Bio, Inc. (Nasdaq: PALI): Advancing Therapeutics for Autoimmune Diseases Palisade Bio, Inc., a leading clinical-stage biopharmaceutical company, has announced a major milestone in its quest to develop novel therapeutics for patients with autoimmune, inflammatory, and fibrotic diseases. The company’s abstract…

Read More